Abstract
Objectives
To evaluate acceptability, safety, and continuation rates of centchroman following
abortion.
Study design
Prospective, observational study. Following spontaneous/induced abortion, women were
offered centchroman, 30-mg tablet twice weekly for first 3 months, then once weekly
with 1 year of follow-up.
Results
Of 120 women who opted for centchroman, continuation rate was 91% at 12 months. There
was one case of user failure and one method failure and 26% had infrequent cycles.
Conclusions
Centchroman is safe, effective, has good acceptance, and continuation rate post abortion
with infrequent menstrual cycles as the main limiting factor for its continuation.
Implications
Centchroman, available in Government scheme for contraception, has good acceptance
and continuation rate post abortion. Its inclusion in contraceptive choices offered
for postabortion contraception can go a long way in spacing of pregnancies, decreasing
repeated unintended pregnancies, unsafe abortions, maternal morbidity, and mortality.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Unintended pregnancy and abortion by income, region and the legal status of abortion: estimates from a comprehensive model for 1990-2019.Lancet Glob Health. 2020; 8: E1152-E1161
- Contraceptive discontinuation in six developing countries: a cause specific analysis.Int Fam Plan Perspect. 1995; 21: 92-97
- Early discontinuation of contraceptive usage in Niger and the Gambia.Fam Plan Perspect. 1992; 18: 145-149
- Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons.Am J Obstet Gynecol. 1998; 179: 577-582
- A prospective study of centchroman users with special reference to its contraceptive benefit.J Evid Based Med Healthc. 2016; 3: 5374-5380
- Clinical pharmacokinetics and interaction of centchroman—a mini review.Contraception. 2010; 81: 275-280
Population Research Institute: News from Latin America. One Less Weapon Against the Unborn: The Abortion Pill Gets Pulled from Market; January 1 2010. Population Research Institute. 〈https://www.pop.org/news-fromlatin-america-one-less-weapon-against-the-unborn-the-abortion-pill-gets-pulledfrom-the-market/〉 (accessed November 23, 2017).
- Reference manual for oral contraceptive pills.Ministry of Health and Family Welfare, Government of India, New Delhi2016
- Scoping review to map evidence on mechanism of action, pharmacokinetics, effectiveness and side effects of centchroman as a contraceptive pill.BMJ Open. 2019; 9e030373
- Dhawn B.N. Results of multicentric trial of centchroman in pharmacology for health in Asia. Allied Publishers, New Delhi, India1988: P432
- Centchroman a better alternative for hormonal oral contraceptive pills.Int J Pharma Biosci. 2011; 2: 587-592
- Medical eligibility criteria for contraceptive use.5th edn. WHO, Geneva, Switzerland2015
- The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions.Int J Gynecol Obstet. 2018; 143: 393-408
- Contraceptive effectiveness versus efficacy.7th edn. Yen & Jaffe's Reproductive Endocrinology, 2014
- National Family Health Survey (NFHS-5), 2019-21: India.IIPS, Mumbai2021
- A study of centchroman users with special reference to its contraceptive benefit.Int J Reprod Contracept Obstet Gynecol. 2019; 8: 4204-4207
- Evaluation of safety profile of centchroman for contraceptive purpose.Natl J Med Allied Sci. 2016; 5: 41-44
Article info
Publication history
Published online: January 31, 2023
Accepted:
January 22,
2023
Received in revised form:
December 31,
2022
Received:
May 24,
2022
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 Elsevier Inc. All rights reserved.
